News|Articles|October 1, 2026

4 Allergy Headlines You Missed in September 2026

Fact checked by: Tim Smith

From a CRISPR therapy's FDA priority review to oral HAE prophylaxis data and a needle-free epinephrine resubmission, 4 allergy stories from September.

September brought regulatory momentum and pivotal trial data in hereditary angioedema (HAE) and anaphylaxis. On the HAE front, the US Food & Drug Administration (FDA) accepted Intellia Therapeutics' Biologics License Application (BLA) for lonvoguran ziclumeran (lonvo-z) with priority review, moving the 1-time CRISPR gene-editing therapy for HAE closer to market. Pharvaris reported that oral deucrictibant extended-release (XR) met its primary endpoint in the phase 3 CHAPTER-3 prophylaxis study.

Related to this article

October 8th, 2026

Viaskin Peanut Patch FAQ: Where It Fits Beside Omalizumab and OIT

With the Viaskin Peanut BLA filed for ages 4 to 7, here's where the patch, omalizumab, and office OIT fit for peanut allergy.With the Viaskin Peanut BLA filed for ages 4 to 7, here's where the patch, omalizumab, and office OIT fit for peanut allergy.

October 9th, 2026

Oral Deucrictibant Speeds Relief of Hereditary Angioedema Attacks

In the phase 3 RAPIDe-3 trial published in The Lancet, median time to symptom relief was 1.28 hours with deucrictibant vs more than 12 hours with placebo.

October 7th, 2026

Remibrutinib Receives FDA Approval for Symptomatic Dermographism

Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.

October 6th, 2026

Residual Asthma Exacerbations on Biologics Vary by Mechanism

Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.

October 6th, 2026

Top Reason for Leaving HAE Attacks Untreated, Survey Finds

Physicians and patients cited perceived mild severity as the top reason for leaving HAE attacks untreated in a recent Adelphi survey.

October 3rd, 2026

Q3 2026 Recap: Allergy News and Updates

Ryaltris pediatric approval, lonvo-z and deucrictibant HAE filings, PVX108 Fast Track, and Palforzia's exit headline Q3 2026 allergy news.

October 9th, 2026

ICONIC-LEAD: Icotrokinra Sustains Psoriasis Skin Clearance at 2 Years

Two-year ICONIC-LEAD data show oral icotrokinra sustained PASI 90 and IGA 0/1 responses in more than 70% of adults and adolescents with plaque psoriasis.

October 9th, 2026

Ixekizumab, Tirzepatide Broaden Biomarker Effects in Psoriasis, Obesity

New TOGETHER-PsO data show ixekizumab plus tirzepatide drove broader immune and metabolic biomarker changes than ixekizumab alone in psoriasis and obesity.